Am J Transplant, Volume 5, Suppl 3 Archives - ATC Abstracts

2015 American Transplant Congress
Comparative Survival Benefits and Costs of an Eplet and Broad Antigen Based Matching System in Deceased Donor Kidney Transplant Allocation Among Indigenous Australians
H. Do Nguyen,¹ G. Wong,^2,3 J. Chapman,² J. Craig,^2,3 L. D'Orsogna,⁴ W. Lim.^1,5
¹School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia; ²Nephrology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; ³School of Medicine, University of New South Wales, Sydney, New South Wales, Australia; ⁴Clinical Immunology, Royal Perth Hospital, Perth, Western Australia, Australia; ⁵Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Aim: To compare the benefits and costs of incorporating an eplet-based matching algorithm to the current allocation of deceased donor kidneys to indigenous Australians.Background: The…
2015 American Transplant Congress
Macrophage Specific β-Catenin Controls ROCK/PTEN Function and Regulates Innate Immunity in Liver Inflammation
S. Yue,¹ X. Zhou,² M. Zhou,¹ Y. Zhai,¹ R. Busuttil,¹ Q. Ying,² J. Kupiec-Weglinski,¹ B. Ke.¹
¹Dumont-UCLA Transplant Center, Dept. of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, Dept. of Stem Cell Biology & Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Background: It has been shown that β-catenin is an important regulator of cell development, regeneration, and carcinogenesis. Our previous studies demonstrated the key role of…
2015 American Transplant Congress
Mitochondrial Hydrogen Sulphide Donor Molecules Are More Effective Against Hypoxic Injury in Renal Tubular Epithelial Cells
G. Aboalsamh,^1,5 M. Saha,² I. Lobb,² J. Grewal,² P. Luke,^1,2,3 M. Wood,⁴ M. Whiteman,⁴ A. Sener.^1,2,3
¹Urology, University of Western Ontario, London, Canada; ²Microbiology and Immunology, University of Western Ontario, London, Canada; ³University of Western Ontario, University of Western Ontario, London, Canada; ⁴Experimental Therapeutics, University of Exeter Medical School, Exeter, England, United Kingdom; ⁵Surgery, King Abdulaziz Medical Center, Jeddah, Saudi Arabia.
Introduction: Ischemia reperfusion injury (IRI) in organ transplant often manifests itself as delayed graft function (DGF). DGF is associated with increased morbidity and deleterious effects…
2015 American Transplant Congress
Early Steroid Withdrawal and Calcineurin Inhibitor Minimization Protocols for Maintenance Immunosuppression: A Single Center 10-Year Experience
R. Lopez-Soler,¹ L. Park,³ J. Martinolich,² D. Conti.¹
¹Transplant Surgery, Albany Medical Center, Albany, NY; ²Surgery, Albany Medical Center, Albany, NY; ³Albany School of Medicine, Albany, NY.
BACKGROUND:Long term use of steroids results in predictable secondary effects that can lead to increased morbidity and mortality. Additionally, long term high levels of Calcineurin…
2015 American Transplant Congress
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 48
K. Budde,¹ C. Sommerer,¹ P. Weithofer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ I. Hauser,¹ R. Stahl,¹ P. Reinke,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ W. Arns.¹
¹Herakles Study Group, Germany; ²Novartis, Pharma, Germany; ³Herakles Study Group, Switzerland.
Aim: To follow up on renal function (GFR) at month (Mo) 48 after kidney transplantation (Tx) in patients (pts) on immunosuppressive regimen with different calcineurin…
2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
M. Stronka, Z. Adamska, L. Cichanska, J. Kubiak, M. Gamrat, M. Karczewski.
Department of Transplantology, General, Vascular and Plastic Surgery, Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland.
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…
2015 American Transplant Congress
The Immunosuppressive Effects of Erythropoietin Do Not Confer Lower Rates of Acute Rejection in Post Kidney Transplant Recipients Receiving Darbepoetin
B. Fischbach,¹ S. Gonzalez,¹ A. Yango,¹ A. Chandrakantan,² A. Rajagopal,² K. Rice,² L. Melton,² Y. Barri,² M. Saim,² N. Onaca,¹ R. Ruiz,¹ M. Levy,¹ G. Klintmalm.²
¹Simmons Transplant Institute, Baylor All Saints Medical Center, Fort Worth, TX; ²Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.
Background: The correction of anemia has been associated with improved kidney allograft outcomes. Recently, erythropoietin was shown to directly suppress alloreactive human T-cells by inhibiting…
2015 American Transplant Congress
Longitudinal Trends in Wait Times and Use of Bridging Locoregional Therapies in Hepatocellular Carcinoma Patients undergoing Orthotopic Liver Transplantation: UNOS Population Study
M. Xing, H. Kim.
Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Background: Trends in bridging locoregional therapies (LRT) and wait times for patients with hepatocellular carcinoma (HCC) undergoing orthotopic liver transplantation (OLT) have not been investigated…
2015 American Transplant Congress
Controlled Hemodilution in Infant Liver Transplants: A Single Center Experience
T. Todo,¹ A. Gallo,¹ J. Mendoza,² T. Pham,¹ C. Esquivel.¹
¹Dept of Surgery, Stanford University, Palo Alto, CA; ²Dept of Anesthesia, Stanford University, Palo Alto, CA.
Introduction: Hepatic artery thrombosis (HAT) remains a major comorbidity in pediatric liver transplants often resulting in graft loss and mortality. Controlled hemodilution decreases blood viscosity…
2015 American Transplant Congress
Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation
D. Halleran,¹ S. Schurman, T. Welch, V. Whittaker.
¹Surgery, State University New York Upstate Medical University, Syracuse, NY; ²Pediatric Nephrology, State University New York Upstate Medical University, Syracuse, NY.
Purpose: We report the outcomes from single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day…

1
2
3
…
170
Next Page »